Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karyopharm’s Selinexor: US FDA Unconvinced By Efficacy In Single-Arm Trial

Executive Summary

Oncologic Drugs Advisory Committee will consider whether approval for Karyopharm’s proposed refractory myeloma therapy selinexor should await results from an ongoing Phase III randomized trial.
Advertisement

Related Content

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
Karyopharm Selinexor Approval Likely Awaits BOSTON Trial, But US FDA Promises To Move Quickly
Slew Of New Drugs Accepted For EU Market Review, Three For Fast Track
Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers

Topics

Advertisement
UsernamePublicRestriction

Register

PS124807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel